Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters
{{output}}
Introduction: Adjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a morbid operation may be difficult, thus neoadjuvant (NA) treatment is p... ...
